Bernard Coulie, Pliant Therapeutics CEO

Pli­ant touts ad­di­tion­al Phase 2a da­ta for oral IPF drug that’s al­ready in a piv­otal study

Pli­ant Ther­a­peu­tics un­veiled more ef­fi­ca­cy da­ta from a small mid-stage tri­al of its lead can­di­date in id­io­path­ic pul­monary fi­bro­sis, which shows that its oral drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.